These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9352698)

  • 21. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
    Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
    Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
    de Mey C; Michel MC; McEwen J; Moreland T
    Eur Urol; 1998; 33(5):481-8. PubMed ID: 9643668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Rutks I
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
    Okada H; Kamidono S; Yoshioka T; Okuyama A; Ozono S; Hirao Y; Okajima E; Yamamoto K; Kishimoto T; Park Y; Kurita T
    BJU Int; 2000 Apr; 85(6):676-81. PubMed ID: 10759664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
    Dunn CJ; Matheson A; Faulds DM
    Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
    Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
    BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
    Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P; Evans CP; Moon T
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia.
    Lin KH; Lin YW; Wen YC; Lee LM
    Aging Male; 2012 Dec; 15(4):246-52. PubMed ID: 23067262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.
    Curtis SP; Eardley I; Boyce M; Larson P; Haesen R; Gottesdiener K; Gertz BJ
    Br J Clin Pharmacol; 2000 Mar; 49(3):269-73. PubMed ID: 10718783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.